Answers are grounded in this paper and cite their sources.
Asthma remains uncontrolled in many patients receiving inhaled corticosteroid/long-acting β 2 -agonist (ICS/LABA), suggesting that guideline-recommended escalation to triple therapy is often delayed. We report outcomes in patients with uncontrolled, infrequently exacerbating asthma (understudied in traditional randomized controlled trials) stepping up from ICS/LABA to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) from the PERFORM trial. PERFORM, a randomized, open-label, active-controlled, pragmatic trial in symptomatic adults with uncontrolled, infrequently exacerbating asthma, evaluated the effectiveness and safety of FF/UMEC/VI versus usual care ICS/LABA. Outcomes included trough forced expiratory volume in 1 s (FEV 1 ), asthma control (Asthma Control Questionnaire [ACQ-5/-6/-7]), and achieving clinical remission at Week 52 for the step-up (participants treated with ICS/LABA pre-randomization) and overall population. Safety was assessed throughout the study. Overall, 783 of 1236 participants in PERFORM received ICS/LABA pre-randomization, with 392 and 391 randomized to FF/UMEC/VI and ICS/LABA, respectively. Statistically significant improvements in trough FEV 1 were observed for FF/UMEC/VI versus ICS/LABA at Week 24 and were durable to Week 52 (least squares means treatment difference in change from baseline [95% confidence interval (CI)]: 66 ml [29, 103] and 67 ml [28, 106] at Weeks 24 and 52). FF/UMEC/VI showed greater odds of achieving ≥ 0.5-point improvement from baseline in ACQ-7 total score at Week 24 and achieving clinical remission at Week 52 versus ICS/LABA (adjusted odds ratio [95% CI]: 1.54 [1.12, 2.12] and 2.78 [1.82, 4.24]; not multiplicity adjusted). Results (including the Week 52 safety profile) were similar to the overall PERFORM population. Escalation to FF/UMEC/VI from ICS/LABA improved lung function, asthma control, and clinical remission, with no unexpected safety findings versus usual care ICS/LABA at Weeks 24 and 52, consistent with the overall PERFORM population. Initiation with FF/UMEC/VI may address the unmet need for optimized treatment in patients with uncontrolled, infrequently exacerbating asthma. Trial Registration : GSK ID: 219912/NCT06372496. Supplementary file1 (MP4 149035 KB)
No takes yet. Share an insight, caveat, or question.
Oppenheimer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: